Inotuzumab Ozogamicin
Refractory B Lymphoblastic Lymphoma
University of Washingtonantibody_drug_conjugatePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Refractory B Lymphoblastic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE University of Washington | Phase 2 | BB |
VINCRISTINE SULFATE ECOG-ACRIN Cancer Research Group | Phase 2 | B |
Inno-206 University of Washington | Phase 2 | B |
ETOPOSIDE University of Washington | Phase 2 | B |
PREDNISONE TABLETS University of Washington | Phase 2 | B |
View all 16 →
Same molecule, other indications
Inotuzumab Ozogamicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →